TAIWAN LIPOSOME/S (TLC) Expected to Post Earnings of -$0.15 Per Share

Equities research analysts expect TAIWAN LIPOSOME/S (NASDAQ:TLC) to announce earnings per share of ($0.15) for the current quarter, Zacks reports. Two analysts have made estimates for TAIWAN LIPOSOME/S’s earnings, with the highest EPS estimate coming in at ($0.08) and the lowest estimate coming in at ($0.22). TAIWAN LIPOSOME/S reported earnings per share of ($0.10) in the same quarter last year, which would indicate a negative year-over-year growth rate of 50%. The business is expected to announce its next earnings results on Friday, May 10th.

On average, analysts expect that TAIWAN LIPOSOME/S will report full year earnings of ($0.91) per share for the current fiscal year, with EPS estimates ranging from ($1.16) to ($0.54). For the next financial year, analysts forecast that the business will report earnings of ($1.52) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for TAIWAN LIPOSOME/S.

TAIWAN LIPOSOME/S (NASDAQ:TLC) last announced its quarterly earnings results on Monday, April 1st. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.01. The company had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.47 million. TAIWAN LIPOSOME/S had a negative net margin of 1,442.64% and a negative return on equity of 167.30%.

Several equities research analysts recently issued reports on TLC shares. Zacks Investment Research lowered shares of TAIWAN LIPOSOME/S from a “hold” rating to a “sell” rating in a report on Tuesday, March 19th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $11.00 price target on shares of TAIWAN LIPOSOME/S in a report on Monday, March 18th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of TAIWAN LIPOSOME/S in a report on Thursday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $10.33.

A hedge fund recently bought a new stake in TAIWAN LIPOSOME/S stock. Millennium Management LLC bought a new position in shares of TAIWAN LIPOSOME/S (NASDAQ:TLC) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 109,500 shares of the company’s stock, valued at approximately $602,000. Millennium Management LLC owned about 0.34% of TAIWAN LIPOSOME/S at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.17% of the company’s stock.

Shares of TAIWAN LIPOSOME/S stock opened at $5.83 on Thursday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.19 and a current ratio of 3.45. TAIWAN LIPOSOME/S has a 1 year low of $5.02 and a 1 year high of $11.00.

About TAIWAN LIPOSOME/S

Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.

Recommended Story: How to execute a trade ex-dividend strategy?

Get a free copy of the Zacks research report on TAIWAN LIPOSOME/S (TLC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TAIWAN LIPOSOME/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TAIWAN LIPOSOME/S and related companies with MarketBeat.com's FREE daily email newsletter.